Vator Securities advises Moberg Pharma on 150 MSEK Rights Issue
Vator Securities acts as Financial Adviser in connection with the transaction raising approximately SEK 150 million.
Moberg Pharma is a Specialty Pharma company focused on developing and commercialising proprietary, acquired and licensed products globally, from clinical development of products based on proven substances to commercialisation.Read More
An unacceptable misunderstanding is circulating in the market
Our jaws drop to the floor when we see the market selling Immunovia on the back of a press release that essentially confirmed the technical performance of IMMray PanCan-d, once again corroborating the robustness of the IMMray platform technology.
As expected, the verification study demonstrated outstanding diagnostic accuracy in line with the previous commercial test model study.Read More
Vator Securities advises A3P Biomedical on 110 MSEK Private Placement
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 110 million.
The SEK 110 million in growth capital was raised from institutional and private investors in Sweden to fund the commercialization of Stockholm3, A3P’s superior prostate cancer test.Read More
Vator Securities advises SciBase on 32 MSEK Warrants
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 32 million.
SciBase AB is a Swedish medical technology company, headquartered in Stockholm, that has developed a unique point of care device for the accurate detection of malignant melanoma.Read More
Equity Sales – Corporate Finance till Vator Securities
I rollen inom Equity Sales kommer ditt fokus att ligga på daglig kontakt med Vator Securities kunder gällande olika emissionserbjudanden.
Du erbjuds en utmanade och utvecklande tjänst i ett snabbväxande bolag med högt driv och engagemang där du kommer att utgöra en viktig del av ett sammansvetsat team och få en unik möjlighet att bli en del av ett framgångsrikt team.Read More
Diamyd® on track for Phase III with 50% LOA, targeting a multibillion-dollar market as a precision medicine game changer
As of September 15th, 2020, the company that was founded in 1984 delivered convincing top-line data – in line with medical consensus view of implementing precision medicine – consistently supporting positive effect of the first-in-class disease-modifying diabetes vaccine Diamyd® in a genetically defined group.
We initiate coverage with an Outperform rating. With a 50% LOA for the lead candidate Diamyd® and 18% LOA for Remygen® our risk-adjusted DCF valuation results in a value for Diamyd Medical of SEK 100 per share, corresponding to an equity value of approximately SEK 6.6 bn non diluted.Read More
CREATE Health delivers another exciting tech, ProMIS, which potentially could open up a world of new IP for Immunovia
In our latest research update on Immunovia, we presented our forecast of a future diagnostic regimen including a combination of proteomics and genomics-based techs to generate timely and correct diagnosis of cancer.
Published in the impactful Nature Communication Biology, Immunovia’s research arm and collaborator CREATE Health demonstrates the powerful combination of the two techs in its novel academic research project, the ProMIS platform.Read More
No one-trick pony – advancing a novel platform-based CNS company
AlzeCure has with its seven-project portfolio multiple shots at goal where each, while early stage, represents a potential multibillion-dollar opportunity.
We update our rating to Outperform and raise the target price to SEK 16 per share, corresponding to an equity value of approximately SEK 600m non-diluted, derived from risk-adjusted DCF valuation of ACD856 and ACD440.Read More